CD33 and acute myeloid leukemia: In contrast with AMG 330, AMG 673 (NCT03224819) is a half-life extended BiTE consisting of the N-terminus of a single-chain IgG Fc region plus CD3/CD33 binding sites currently in phase I clinical trial for adult R/R AML.